IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 20.415
NA - Nord America 14.501
AS - Asia 12.250
SA - Sud America 2.268
AF - Africa 138
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 18
Totale 49.618
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.288
RU - Federazione Russa 8.558
SG - Singapore 4.618
IE - Irlanda 3.513
CN - Cina 2.673
HK - Hong Kong 2.346
BR - Brasile 1.967
UA - Ucraina 1.723
GB - Regno Unito 1.540
IT - Italia 1.501
DE - Germania 1.235
VN - Vietnam 619
FR - Francia 605
KR - Corea 601
FI - Finlandia 536
SE - Svezia 467
IN - India 378
GR - Grecia 351
TR - Turchia 325
JP - Giappone 229
CA - Canada 115
AR - Argentina 113
AT - Austria 85
BD - Bangladesh 76
PK - Pakistan 75
ID - Indonesia 74
NL - Olanda 64
MX - Messico 62
EC - Ecuador 59
IQ - Iraq 54
PL - Polonia 51
BE - Belgio 46
ES - Italia 36
ZA - Sudafrica 34
CO - Colombia 33
CZ - Repubblica Ceca 28
MA - Marocco 28
PY - Paraguay 25
CL - Cile 22
VE - Venezuela 21
AU - Australia 19
SA - Arabia Saudita 18
AZ - Azerbaigian 16
EG - Egitto 16
IL - Israele 16
AE - Emirati Arabi Uniti 15
EU - Europa 15
IR - Iran 15
JO - Giordania 14
UZ - Uzbekistan 14
KE - Kenya 12
DZ - Algeria 11
PE - Perù 11
CH - Svizzera 10
DO - Repubblica Dominicana 10
TN - Tunisia 10
AL - Albania 9
BO - Bolivia 9
HU - Ungheria 8
KG - Kirghizistan 8
MY - Malesia 8
NP - Nepal 8
NZ - Nuova Zelanda 8
LT - Lituania 7
TW - Taiwan 7
HR - Croazia 6
LB - Libano 6
CG - Congo 5
CR - Costa Rica 5
HN - Honduras 5
KZ - Kazakistan 5
RO - Romania 5
SN - Senegal 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
BH - Bahrain 4
BY - Bielorussia 4
ET - Etiopia 4
JM - Giamaica 4
LV - Lettonia 4
MK - Macedonia 4
RS - Serbia 4
AO - Angola 3
GY - Guiana 3
MM - Myanmar 3
OM - Oman 3
PH - Filippine 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
BG - Bulgaria 2
EE - Estonia 2
GA - Gabon 2
GI - Gibilterra 2
KW - Kuwait 2
LK - Sri Lanka 2
ML - Mali 2
NG - Nigeria 2
NO - Norvegia 2
Totale 49.591
Salva come PNG Salva come JPEG
Città #
Dublin 3.495
Moscow 2.736
Jacksonville 2.638
Hong Kong 2.339
Santa Clara 1.844
Chandler 1.692
Singapore 1.690
Wilmington 694
Seoul 575
Princeton 557
Chicago 549
Medford 493
Hefei 451
New York 336
Ashburn 335
Falls Church 334
Boardman 311
San Mateo 292
Bengaluru 288
Beijing 286
Dallas 261
Roxbury 257
Ann Arbor 250
Naples 233
Bremen 231
Ho Chi Minh City 217
Munich 211
The Dalles 209
Caserta 184
São Paulo 166
Woodbridge 161
Cambridge 124
Hanoi 121
Los Angeles 121
Des Moines 118
Nanjing 95
Nuremberg 81
Houston 67
Jinan 64
Rio de Janeiro 60
Elora 59
Turku 57
Mountain View 52
Napoli 50
Belo Horizonte 48
Vienna 45
Shanghai 44
Dong Ket 42
Norwalk 42
Brussels 40
Helsinki 40
Düsseldorf 39
Tianjin 39
Guangzhou 35
Nanchang 35
Aversa 34
Lappeenranta 34
Brasília 33
Curitiba 33
Falkenstein 31
Amsterdam 28
Milan 28
Campinas 27
Shenyang 27
Kraków 26
Tokyo 26
Changsha 25
Columbus 25
Haiphong 25
Quito 24
Brno 23
Brooklyn 23
Goiânia 23
Guarulhos 23
London 23
Auburn Hills 22
Da Nang 22
Jakarta 22
Porto Alegre 22
Ribeirão Preto 22
Venice 22
Salvador 21
San Francisco 21
Istanbul 20
Redwood City 20
Rome 20
Warsaw 18
Zhengzhou 18
Boston 17
Council Bluffs 17
Kunming 17
Taiyuan 17
Dhaka 16
Ercolano 16
Guayaquil 16
Hangzhou 16
Ottawa 16
Baghdad 15
Baku 15
Ninh Bình 15
Totale 26.837
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.386
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 179
ONCOLOGIA MEDICA 174
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 161
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 156
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 156
Beyond N staging in colorectal cancer: Current approaches and future perspectives 155
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 154
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 149
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 140
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 138
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 138
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 137
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 137
AXL is an oncotarget in human colorectal cancer 134
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 134
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 132
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 131
Chronic inflammation and oxidative stress in human carcinogenesis 131
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 129
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 129
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 128
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 128
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 127
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway 125
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 123
Clinical management of advanced gastric cancer: Role of new molecular drugs. 123
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 123
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 123
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 122
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis 121
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 121
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 121
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 121
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 120
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 119
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 119
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 118
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 117
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 116
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 115
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 114
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 114
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 114
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 113
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 113
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 111
Treatment of gastric cancer. 111
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 110
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 110
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 110
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 109
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 108
Immunotherapy for head and neck cancer: Present and future 108
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival 107
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 107
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 106
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 106
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo 106
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 106
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 106
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 106
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 106
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 106
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 105
Farmacogenomica e cancro colorettale 104
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in humancolon cancer cells 103
TRASTUZUMAB RESISTANCE IN BREAST CANCER 103
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 103
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 103
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 102
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 102
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 102
A meta-analysis on the interactionbetween HER-2 expression and response to endocrine treatment in advanced breastcancer 102
Antiangiogenic drugs in non small cell lung cancer treatment 102
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 102
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor 102
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 102
Modified blade: an interventional option in rigid bronchoscopy for non-resectable benign tracheal stenosis 101
Intraoperative ultrasound: "Alternative eye" in lymph nodal dissection in non-small cell lung cancer 101
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer 101
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 101
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 101
Clinical management of metastatic colorectal cancer in the era of precision medicine 101
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 100
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics 100
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 100
A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer 100
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 100
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 100
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 99
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 99
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 99
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 99
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 99
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 99
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 98
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 98
ZD1839 (Iressa): preclinical studies and pharmacology 98
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 98
Totale 12.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.747
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.747
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.151 0 0 0 0 0 42 536 414 69 504 426 160
2021/20224.183 400 171 288 158 1.304 73 83 114 159 165 300 968
2022/20237.055 796 176 392 603 674 567 31 366 3.135 44 136 135
2023/20242.895 245 89 130 249 998 337 61 61 48 27 199 451
2024/20258.974 97 169 120 305 1.245 1.098 894 846 1.204 1.773 650 573
2025/202617.485 1.423 1.752 2.045 1.998 2.916 7.351 0 0 0 0 0 0
Totale 50.624